CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia-Reference-Cited by-同舟云学术

CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia

Published:2020-11 Issue:5 Volume:111 Page:
ISSN:0026-4806
Container-title:Minerva Medica
language:
Short-container-title:Minerva Med

Author:

Cafaro Alessandro,Giannini Maria B.,Silimbani Paolo,Cangini Delia,Masini Carla,Ghelli Luserna Di Rorà Andrea,Simonetti Giorgia,Martinelli Giovanni,Cerchione Claudio

Publisher

Edizioni Minerva Medica

Subject

General Medicine

Link

https://www.minervamedica.it/pdf.php?cod=R10Y2020N05A0455

Reference38 articles.

1. Acute myeloid leukaemia

2. Current and emerging therapies for acute myeloid leukemia

3. Incidence, survival and prevalence of myeloid malignancies in Europe

4. The incidence of secondary leukemias;Leone G;Haematologica,1999

5. The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 years

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vesicular Nanosystem as a Promising Platform for the Management of Cancer;Interdisciplinary Cancer Research;2024

2. An insight of various vesicular systems, erythrosomes, and exosomes to control metastasis and cancer;Advances in Cancer Biology - Metastasis;2023-07

3. Smart and Generalizable Cytarabine Derivative-Triggered Nanoparticles for Synergistic Therapy of Relapsed/Refractory Acute Myeloid Leukemia;ACS Applied Materials & Interfaces;2023-05-30

4. Liposome-Encapsulated Melphalan Exhibits Potent Antimyeloma Activity and Reduced Toxicity;ACS Omega;2022-12-29

5. Myelodysplastic Syndromes;Holland‐Frei Cancer Medicine;2022-10-21